Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
81 employees
US-based Venatorx Pharmaceuticals develops solutions for multi-drug-resistant bacterial and tough viral infections.
HQ
Founded
2010
Founded in Malvern, United States, Venatorx Pharmaceuticals is a private company dedicated to discovering and developing novel anti-infectives aimed at treating multi-drug-resistant (MDR) bacterial infections and challenging viral infections. The company's core mission is to improve health outcomes for patients facing these severe health threats. Venatorx’s product pipeline includes innovative antibiotics and antiviral therapies designed to address the growing issue of drug resistance, which poses a significant public health risk globally.
Notable figures affiliated with Venatorx Pharmaceuticals include experienced scientists and industry leaders who contribute to its research and development efforts. The company has attracted investments from reputable venture capital firms, which underscores confidence in its mission and potential impact. Key achievements include successful preclinical and clinical trials that have demonstrated the efficacy of its drug candidates. Venatorx Pharmaceuticals has made a substantial impact by advancing treatments that could potentially save lives and curb the spread of resistant infections.
Operating Status
Active
Main Product(s)
Anti-Infectives
Technology
Biotech
Tags
Pharma
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Government
Geographic Exposure
United States
When was Venatorx Pharmaceuticals founded?
Venatorx Pharmaceuticals was founded in 2010.
Where is Venatorx Pharmaceuticals's headquarters located?
Venatorx Pharmaceuticals's headquarters is located in Malvern, PA, US.
When was Venatorx Pharmaceuticals's last funding round?
Venatorx Pharmaceuticals's most recent funding round was for $24.7M (USD) in September 2022.
How many employees does Venatorx Pharmaceuticals have?
Venatorx Pharmaceuticals has 81 employees as of Feb 5, 2024.
How much has Venatorx Pharmaceuticals raised to-date?
As of July 05, 2023, Venatorx Pharmaceuticals has raised a total of $165.7M (USD) since Sep 2, 2022.
Add Comparison
Total Raised to Date
$165.7M
USD
Last Update Sep 2, 2022
Last Deal Details
$24.7M
USD
Sep 2, 2022
Series Unknown
Current Employees
81
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts